Objective  To explore the effect of sequential therapy with butylphthalide on the risk of post-stroke epilepsy (PSE) in patients with cerebral infarction.

Methods  The clinical data of patients with cerebral infarction hospitalized in Langfang People's Hospital from October, 2016 to October, 2022 were selected and analyzed. Patients receiving butylphthalide sequential treatment were included in the butylphthalide group, patients who were hospitalized at the same time with matching gender, age (±5 years), basic disease, clinical drug treatment scheme and follow-up period but did not receive butylphthalide treatment were included in the control group. The general clinical data, laboratory examination results on admission, and incidence of PSE in the two groups were compared, and multivariate Logistic regression was used to analyze the correlation between sequential therapy with butylphthalide and PSE occurrence in patients with cerebral infarction.

Results  A total of 1,200 patients were included, with 600 patients in each group. There was no significant difference in general clinical data such as sex, age, complications and living habits between the two groups (P>0.05). There were no significant differences between the two groups in the patients distribution of TOAST classification, NIHSS score (P>0.05). The incidence of PSE in butylphthalide group was significantly lower than that in control group (4.17% vs. 7.83%, P<0.05). The application of sequential treatment with butylphthalide was a protective factor for PSE occurrence in patients with cerebral infarction [OR=0.352, 95%CI (0.151, 0.821), P=0.016].

Conclusion  Sequential treatment with butylphthalide can reduce the risk of post-stroke epilepsy in patients with cerebral infarction.

1.Zhang Y, Ren Y, Chen X, et al. Role of butylphthalide in immunity and inflammation: butylphthalide may be a potential therapy for anti-inflammation and immunoregulation[J]. Oxid Med Cell Longev, 2022, 2022: 7232457. DOI: 10.1155/2022/7232457.

2.Yang Q, Hu YD, Wang XF, et al. Dl-3n-butylphthalide reduces epileptiform activity through GluA2-lacking calcium-permeable AMPARs in epilepsy models[J]. Oncotarget, 2017, 8(58): 98242-98257. DOI: 10.18632/oncotarget.21529.

3.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志, 2024, 57(6): 523-559. [Neurology Branch of Chinese Medical Association, Cerebrovascular Disease Group of Neurology Branch of Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chinese Journal of Neurology, 2024, 57(6): 523-559.] DOI: 10.3760/cma.j.cn113694-20240410-00221.

4.Tanaka T, Fukuma K, Abe S, et al. Association of cortical superficial siderosis with post-stroke epilepsy[J]. Ann Neurol, 2023, 93(2): 357-370. DOI: 10.1002/ana.26497.

5.Huang YW, Yin XS, Li ZP. Association of the systemic immune-inflammation index (SII) and clinical outcomes in patients with stroke: a systematic review and Meta-analysis[J]. Front Immunol, 2022, 13: 1090305. DOI: 10.3389/fimmu.2022.1090305.

6.Mastrorilli D, Mezzetto L, D'Oria M, et al. National Institutes of Health stroke scale score at admission can predict functional outcomes in patients with ischemic stroke undergoing carotid endarterectomy[J]. J Vasc Surg, 2022, 75(5): 1661-1669, e1662. DOI: 10.1016/j.jvs.2021.11.079.

7.梁宝毅, 黄涯, 韩静, 等. 丁苯酞联合拉莫三嗪治疗脑卒中后癫痫的临床疗效及药物经济学评价[J]. 临床合理用药, 2024, 17(33): 68-71. DOI: 10.15887/j.cnki.13- 1389/r.2024.33.018.

8.陈德艳. 卡马西平联合丁苯酞治疗卒中后癫痫患者疗效及认知改变分析[J]. 山西医药杂志, 2022, 51(13): 1480-1481. DOI: 10.3969/j.issn.0253-9926.2022.13.012.

9.王少津, 陈海荣, 潘碧云. 丁苯酞联合左乙拉西坦治疗脑卒中后继发性癫痫的效果[J]. 分子诊断与治疗杂志, 2023, 15(9): 1646-1649. [Wang SJ, Chen HR, Pan BY. Effect of butylphthalide combined with levetiracetam on the treatment of secondary epilepsy after stroke[J]. Journal of Molecular Diagnosis and Therapy, 2023, 15(9): 1646-1649.] DOI: 10.3969/j.issn.1674-6929.2023.09. 041.

10.Zhao S, Liu F, Shi W, et al. DL-3-n-butylphthalide promotes hippocampal neurogenesis and reduces mossy fiber sprouting in chronic temporal lobe epilepsy rats[J]. BMC Neurol, 2022, 22(1): 3. DOI: 10.1186/s12883-021-02516-x.

11.Ye X, Rong Z, Li Y, et al. Protective role of L-3-n-butylphthalide in cognitive function and dysthymic disorders in mouse with chronic epilepsy[J]. Front Pharmacol, 2018, 9: 734. DOI: 10.3389/fphar.2018.00734.

12.冯晓军. 阿司匹林加氯吡格雷联合丁苯酞治疗脑梗死患者的疗效和用药安全性及对其血清学指标的影响分析[J]. 中国现代药物应用, 2024, 18(13): 74-77. [Feng XJ. Analysis of efficacy and medication safety of aspirin combined with clopidogrel in patients with cerebral infarction and its influence on serological indicators[J]. Chinese Journal of Modern Drug Application, 2024, 18(13): 74-77.] DOI: 10.14164/j.cnki.cn11-5581/r.2024.13.020.

13.常旭华. 丁苯酞联合他汀类降脂药治疗急性脑梗死的疗效及安全性分析[J]. 安徽医专学报, 2024, 23(1): 54-56. [Chang XH. Efficacy and safety analysis of buterphthalin combined with statin lipid-lowering drugs in acute cerebral infarction[J]. Journal of Anhui Medical College, 2024, 23(1): 54-56.] DOI: 10.20072/j.cnki.issn2097-0196. 2024.01.018.

14.张怡. 丁苯酞联合替罗非班治疗急性大面积脑梗死的效果及安全性[J]. 临床合理用药, 2024, 17(4): 52-55. DOI: 10.15887/j.cnki.13-1389/r.2024.04. 015.

15.张萍, 李洁, 易兴阳, 等. 丁苯酞预防脑梗死后早期神经功能恶化的真实世界研究[J]. 华西医学, 2023, 38(5): 680-687. [Zhang P, Li J, Yi XY, et al. A real-world study of DL-3-n-butylphthalide in preventing early neurological deterioration after cerebral infarction[J]. West China Medical Journal, 2023, 38(5): 680-687.] DOI: 10.7507/1002-0179.202303196.

16.夏飞, 李勇光, 邓小容, 等. 丁苯酞注射液对三种常见TOAST分型急性缺血性脑卒中疗效比较的回顾性研究[J]. 药物流行病学杂志, 2023, 32(5): 498-505. [Xia F, Li YG, Deng XR, et al. Retrospective study on efficacy comparison of butylphthalide injection on the three commen types of acute cerebral infarction with TOAST classification[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(5): 498-505.] DOI: 10.19960/j.issn.1005-0698.202305003.

17.Guo ZN, Yue BH, Fan L, et al. Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): a randomized, controlled, multicenter trial[J]. J Cereb Blood Flow Metab, 2023, 43(10): 1702-1712. DOI: 10.1177/0271678X231168507.

18.Liu CY, Zhao ZH, Chen ZT, et al. DL-3-n-butylphthalide protects endothelial cells against advanced glycation end product-induced injury by attenuating oxidative stress and inflammation responses[J]. Exp Ther Med, 2017, 14(3): 2241-2248. DOI: 10.3892/etm.2017.4784.

19.Han L, Wang Q, Liu X. The effect of butylphthalide on aminoacid content in the brain of epileptic mice[J]. Minerva Pediatr (Torino), 2022, 74(6): 746-751. DOI: 10.23736/S2724-5276.16.04415-7.

20.Guo J, Guo J, Li J, et al. Statin treatment reduces the risk of poststroke seizures[J]. Neurology, 2015, 85(8): 701-707. DOI: 10.1212/WNL.0000000000001814.

21.刘艳华, 王冶, 鲁东, 等. 依达拉奉联合丙戊酸钠治疗脑卒中后癫痫的疗效及对炎性因子的影响[J]. 黑龙江医药, 2022, 35(1): 52-55. [Liu YH, Wang Z, Lu D, et al. Efficacy of edaravone combined with sodium valproate in the treatment of epilepsy after stroke and its effect on inflammatory factors[J]. Heilongjiang Medicine Journal, 2022, 35(1): 52-55.] DOI: 10.14035/j.cnki.hljyy.2022.01.019.